'Tmz' presentation slideshows

Temozolomide resistance in glioblastoma multiforme (GBM) and its application

Oncology Nursing 2016. Temozolomide resistance in glioblastoma multiforme (GBM) and its application for drug development. Sang Y. Lee, Ph.D. Assistant Professor Pennsylvania State University College of Medicine. Conflict of interest. ? None. Contents. ? Brain tumor & GBM

561 views • 43 slides

Clinical Trials Update in Neuro-Oncology Dr Susan Short

Clinical Trials Update in Neuro-Oncology Dr Susan Short. November 2010. Chair NCRI brain tumour clinical study group CRUK Senior Fellow Consultant in Clinical Oncology, UCLH. Challenges. -0.5%. Challenges. Age distribution. From McKinney et al 2005, UK age specific incidence data

552 views • 36 slides

Impact of DNA Repair Mechanisms on Resistance to alkylating therapeutic agents

Impact of DNA Repair Mechanisms on Resistance to alkylating therapeutic agents. NH 2. NH 2. C. O. C. O. N. N. N. N. N. N. CH 3. CH 3. N. NH 2. N. N. H. O. C. O. N. N. N. N. CH 3. CH 3. N. TMZ. MTIC. DITC. NH 2. CH 3. O. C. O. N. N. N. N. N. H 2 N. N.

321 views • 23 slides

TREATMENT PLANNING Modelling chemo-hadron therapy

TREATMENT PLANNING Modelling chemo-hadron therapy. Lara Barazzuol | Valencia | 19 June 2009. Contents:. Background - PARTNER project Glioblastoma & treatment - Research questions Clinical Trial model: outline - Temozolomide: Scenarios 1 and 2

332 views • 17 slides

TREATMENT PLANNING Modelling chemo-hadron therapy

TREATMENT PLANNING Modelling chemo-hadron therapy. Lara Barazzuol | Valencia | 19 June 2009. Contents:. Background - PARTNER project Glioblastoma & treatment - Research questions Clinical Trial model: outline - Temozolomide: Scenarios 1 and 2

264 views • 17 slides

Co-Principal Investigators: Sandra Strauss, MD, PhD University College London Rashmi Chugh , MD

ESP1/SARC025. ESP1/SARC025 Global Collaboration: A Phase I Study of a Combination of the PARP inhibitor, Niraparib and Temozolomide in Patients with Previously Treated, incurable Ewing Sarcoma. Co-Principal Investigators: Sandra Strauss, MD, PhD University College London

205 views • 10 slides

CD133-

Supplementary Figure 1. G073. HUVECs. 40. 30. % PI +. 20. CD133 +. 10. E030. 0. control. TMZ 10 ? M. TMZ 50 ? M. TMZ 100 ? M. CD133+. Isotype control CD31-PE CD105-PE. G077. G408. 100. 20. 80. 15. 60. % PI +. % PI +. 10. 40. 5. 20. 0. 0. control. control.

150 views • 5 slides

***

121 views • 1 slides